Drug Type Small molecule drug |
Synonyms Siremadlin Succinate, HDM-201, NVP-HDM201 |
Target |
Mechanism MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H24Cl2N6O4 |
InChIKeyAGBSXNCBIWWLHD-FQEVSTJZSA-N |
CAS Registry1448867-41-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematopoietic stem cell transplantation | Phase 2 | DE | 23 Feb 2023 | |
Hematopoietic stem cell transplantation | Phase 2 | IT | 23 Feb 2023 | |
Hematopoietic stem cell transplantation | Phase 2 | ES | 23 Feb 2023 | |
Locally Advanced Soft Tissue Sarcoma | Phase 2 | FR | 15 Apr 2022 | |
Metastatic Soft Tissue Sarcoma | Phase 2 | FR | 15 Apr 2022 | |
Acute Myeloid Leukemia | Phase 2 | - | 15 Nov 2019 | |
Post-polycythemia vera myelofibrosis | Phase 2 | AU | 26 Sep 2019 | |
Post-polycythemia vera myelofibrosis | Phase 2 | AU | 26 Sep 2019 | |
Post-polycythemia vera myelofibrosis | Phase 2 | AU | 26 Sep 2019 | |
Post-polycythemia vera myelofibrosis | Phase 2 | AU | 26 Sep 2019 |
Phase 1/2 | 23 | (SIR 20mg) | dfamwglwyh(lshdrlklah) = rrogexsycj odqvjoicqm (jfdqqnykok ) View more | Positive | 15 Nov 2022 | ||
(SIR 30mg) | dfamwglwyh(lshdrlklah) = pcsvqxueai odqvjoicqm (jfdqqnykok ) View more | ||||||
NCT03940352 (ASH2021) Manual | Phase 1 | - | Venetoclax+Siremadlin | piwwmuqrjy(xbocgwotpg) = fgtopahdbi elmjosrhai (ipbreenvsk ) View more | Positive | 05 Nov 2021 | |
Phase 1 | 85 | Regimen 1A | zqforsabbh(wmxvcwtprj) = 12%; 0%; 20%; 16% anlwqawfrc (vqaomxpiin ) View more | Positive | 01 Jul 2017 | ||
Regimen 1B | |||||||
Phase 1 | 37 | hijglxkdth(eyrabpjjmx) = n=1 pazrimyszv (zxedbobwuo ) View more | - | 01 Jul 2017 |